The results showed that the incidence of vomiting in the treatment of breast cancer in the albumin paclitaxel group was lower than that in the docetaxel group (Z = 0.34, P=0.76), which indicated that the difference shown in the results was not statistically significant. The gene discussed is ALB; the disease is breast carcinoma.